This 2013 study assessed the impact of 600 mg/day alpha-lipoic acid (ALA) supplementation on cognitive function in 126 Alzheimer’s disease (AD) patients, divided into two groups based on the presence (Group A) or absence (Group B) of diabetes mellitus (DM). Cognitive assessments included MMSE, ADAS-Cog, CIBIC, CDR, and ADFACS. Results
This Phase III clinical trial evaluated the efficacy of LMTM, a tau aggregation inhibitor, as monotherapy in patients with mild Alzheimer’s disease (AD). The study involved 800 participants randomized to receive either 100 mg or 4 mg of LMTM twice daily. Prior to unblinding, the analysis plan was revised to
This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and tolerability of choline alfoscerate (CA) in treating cognitive impairment in patients with mild to moderate Alzheimer’s disease (AD). A total of 261 patients were randomized to receive either CA (400 mg capsules) or placebo, three times daily for 180 days.
This article reports on two randomized, double-blind, placebo-controlled Phase 3 trials evaluating bapineuzumab, a humanized monoclonal antibody targeting β-amyloid, in patients with mild-to-moderate Alzheimer’s disease (AD). One trial enrolled APOE ε4 carriers, and the other enrolled noncarriers. Despite some biomarker changes—such as reduced cerebrospinal fluid phosphorylated tau levels and stabilization
This randomized, double-blind, placebo-controlled trial assessed the efficacy of high-dose B vitamin supplementation (folic acid 5 mg, vitamin B6 25 mg, and vitamin B12 1 mg daily) in slowing cognitive decline among 409 individuals with mild to moderate Alzheimer’s disease over 18 months. Despite significant reductions in plasma homocysteine levels
This open-label pilot study assessed the potential of alpha-lipoic acid (ALA) as an adjunctive treatment for Alzheimer’s disease (AD). Nine patients with AD or related dementias received 600 mg of ALA daily alongside standard acetylcholinesterase inhibitor therapy over an average of 337 days. Cognitive performance, measured by MMSE and ADAS-Cog,
